Press Releases H. Lundbeck A/S

Equities

HLUN B

DK0061804770

Pharmaceuticals

Real-time Estimate Cboe Europe Other stock markets 12:48:02 17/04/2026 BST			5-day change	1st Jan Change
42.36 ^DKK	+1.49%		+4.66%	-2.09%

04-13	Lundbeck to present new neurology data at upcoming congress	FW
03-23	H. Lundbeck Price Target Down as AlphaValue/Baader Europe Expects Patent Expirations to Weigh on Growth	MT

Press Releases

04-13	Lundbeck to showcase new neurology data at the American Academy of Neurology Annual Meeting	AQ
03-30	H Lundbeck A/S : Remuneration Policy 2026 (Remuneration Policy 2026)	PU
03-18	Lundbeck held its Annual General Meeting on 18 March 2026 at the company's registered office	AQ
03-18	H Lundbeck A/S : Presentation (AGM Presentation 2026)	PU
03-16	Lundbeck advances Parkinson's research with new Phase 1b data at AD/PD™ 2026	AQ
03-10	Lundbeck appoints Chief AI Officer	AQ
03-09	Lundbeck announces last patient randomized ahead-of-schedule in Phase 3 MASCOT trial	AQ
02-17	H Lundbeck A/S : Remuneration Report 2025 (Remuneration Report 2025)	PU
02-17	H Lundbeck A/S : Registration form (Registration form)	PU
02-17	H Lundbeck A/S : Annual Report 2025 (Annual Report)	PU
02-17	H Lundbeck A/S : Appendix 1 Amended Remuneration Policy 2026 (Appendix 1 Amended Remuneration Policy 2026)	PU
02-17	To the shareholders of H. Lundbeck A/S	AQ
02-12	Lundbeck announces positive phase IIb top-line results with bocunebart (Lu AG09222; anti-PACAP mAb) in migraine prevention	AQ
02-10	H Lundbeck A/S : Transcript (Transcript FY25)	PU
02-04	Transactions with shares and linked securities in Lundbeck made by executives and their closely associated parties	AQ
02-04	H Lundbeck A/S : Annual Report (Lundbeck Annual Report 2025)	PU
02-04	H Lundbeck A/S : Investor Presentation (Lundbeck InvestorDeck FY 2025 1)	PU
02-04	H Lundbeck A/S : Release (Corporate Release FY2025 Final)	PU
02-04	H Lundbeck A/S : Investor Presentation (Lundbeck InvestorDeck FY 2025)	PU
02-04	Lundbeck Annual Report 2025	AQ
02-04	Record 2025 performance with revenue up 13% CER and adjusted EBITDA up 24% CER positions Lundbeck for continued growth in 2026	AQ
01-30	Lundbeck presents new real-world data highlighting meaningful improvements in patients severely impacted by migraine initiating Vyepti® (eptinezumab), at HCOP Annual Conference	AQ
12-08	Transactions with shares and linked securities in Lundbeck made by executives and their closely associated parties	AQ
12-06	Lundbeck announces positive Phase 2 long-term data for bexicaserin in rare childhood-onset epilepsies, at American Epilepsy Society (AES) Annual Meeting	AQ
12-02	Lundbeck to present comprehensive new bexicaserin dataset in patients with rare childhood-onset epilepsies, at American Epilepsy Society (AES) Annual Meeting	AQ